NCM
CNCE

Nantahala Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Nantahala Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,732,388
Closed -$10.1M – 134
2022
Q4 		$10.1M Sell
1,732,388
-54,771
-3% -$288K 0.66% 36
2022
Q3 		$12M Buy
1,787,159
+127,319
+8% +$772K 0.77% 35
2022
Q2 		$6.99M Buy
+1,659,840
New +$6.57M 0.35% 53

Nantahala Capital Management's CNCE Position: Q1 2023 in Review

Nantahala Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,732,388 shares — an estimated $10.1M sold.

Nantahala Capital Management first reported a position in CNCE in Q2 2022 and held it in 3 quarters. The position peaked at $12M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • Nantahala Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Nantahala Capital Management sold 1,732,388 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $10.1M.
  • Nantahala Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2022 and held it in 3 quarters.
  • Nantahala Capital Management's Concert Pharmaceuticals, Inc. position peaked at $12M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Nantahala Capital Management's 13F filing for Q1 2023, filed 15 May 2023.